Exploring the Future of the Pharmaceutical Industry and the Healthcare System â The Benefits of Electronic Health Records Becoming a Reality (original) (raw)
Related papers
Clinical Pharmacology & Therapeutics
Judicious use of real-world data (rWD) is expected to make all steps in the development and use of pharmaceuticals more effective and efficient, including research and development, regulatory decision making, health technology assessment, pricing, and reimbursement decisions and treatment. a "learning healthcare system" based on electronic health records and other routinely collected data will be required to harness the full potential of rWD to complement evidence based on randomized controlled trials. We describe and illustrate with examples the growing demand for a learning healthcare system; we contrast the exigencies of an efficient pharmaceutical ecosystem in the future with current deficiencies highlighted in recently published organisation for economic Co-operation and Development (oeCD) reports; and we reflect on the steps necessary to enable the transition from healthcare data to actionable information. a coordinated effort from all stakeholders and international cooperation will be required to increase the speed of implementation of the learning healthcare system, to everybody's benefit.
Meaningful Use of Electronic Health Records: Experiences From the Field and Future Opportunities
JMIR medical informatics, 2015
With the aim of improving health care processes through health information technology (HIT), the US government has promulgated requirements for "meaningful use" (MU) of electronic health records (EHRs) as a condition for providers receiving financial incentives for the adoption and use of these systems. Considerable uncertainty remains about the impact of these requirements on the effective application of EHR systems. The Agency for Healthcare Research and Quality (AHRQ)-sponsored Centers for Education and Research in Therapeutics (CERTs) critically examined the impact of the MU policy relating to the use of medications and jointly developed recommendations to help inform future HIT policy. We gathered perspectives from a wide range of stakeholders (N=35) who had experience with MU requirements, including academicians, practitioners, and policy makers from different health care organizations including and beyond the CERTs. Specific issues and recommendations were discussed...
Objective: The Electronic Health Records for Clinical Research (EHR4CR) project aims to deliver a new technological platform and business model to enable the re-use of patient information from electronic health records (EHRs) for clinical research in Europe. An EU electronic survey (e-survey) was conducted to identify opportunities and issues pertaining to the development and implementation of cost-effective EHR4CR clinical services. Methods: The EU e-survey was conducted in two waves: with participating stakeholders from the public and private sectors involved in the EHR4CR consortium, and with non-participating informed stakeholders. Results: The results confirm a high interest in re-using EHR data for clinical research with the objective of optimizing drug development efficiency and access to innovative medicines in Europe. Key challenges include privacy protection, systems interoperability, patient acceptance, and ethical considerations. Conclusions: The re-use of EHR data for c...
The Electronic Health Records for Clinical Research Project
There is increasing international interest in the potential for re-using routinely collected electronic hospital patient health records, for clinical research purposes. This opportunity is especially attractive to the pharmaceutical industry that invests significantly in clinical trials and recognizes the potential efficiency gains that might be made,and the possible resulting acceleration in getting new medicines to market. This paper summarizes the objectives, work plan and first year results of the Electronic Health Record for Clinical Research (EHR4CR) four-year project, sponsored through the EU Innovative Medicines Initiative. EHR4CR aims to design and demonstrate a scalable and cost-effective approach to inter-operability, or the ability for health information systems to work together within and across organizational boundaries, effectively connecting Electronic Health Record systems (EHRs) and Clinical Research. The project is developing an innovative and reliable platform th...
Electronic Health Records for Drug Repurposing: Current Status, Challenges, and Future Directions
Clinical Pharmacology & Therapeutics, 2020
It is well recognized that the global pharmaceutical industry now faces challenges such as high costs and low productivity when developing new drugs (e.g., it is estimated that the average cost for developing a new drug ranges from US 2billionto2 billion to 2billionto3 billion with the total time to bring it to the market being about 13-15 years). 1 Therefore, drug repurposing (also called drug repositioning/reprofiling), which finds new indications for existing drugs, has received great attention in the past decade. Drug repurposing can reduce drug development time, while improving success rates because the toxicity profiles of existing drugs are already known. Studies have shown that new applications for repurposed drugs have nearly a 30% success rate for US Food and Drug Administration (FDA) approval, whereas traditional new drug applications have < 10% approval rate.
Big Data and Electronic Health Record in Pharmacy: A Systematic Review
Journal of Advanced Scientific Research
As technology is advancing in medicine, the form in which medical data are treated has also changed over time. Big Data are huge data sets that are very big and complicated that it is difficult to compile, exchange and analyse them. Big data is reliable and helps in better decision making, reduced costs and improved organizational skills. Big data is classified as 'variety, volume, velocity, value, and veracity'. Electronic Health Record (EHR) the whole is known to be big data. EHR is essentially large due to the complexity and number of patients and the amount of information on each patient and is gathered for a variety of purposes, such as clinical care, accounting, auditing and quality control. Pharmacy information is an integral part of the electronic health record (EHR) data and can directly influence the quality of treatment and the safety of patients. From data related to pharmacy which is introduced by the patients in the course of visits to the data put down by the ...